Speakers
Programmed at NextGen, in alphabetical order.
Sponsors
The companies behind the program. Tiers as disclosed.
Agenda
Selected from 8 sessions.
- Monday15June09:25 - 09:50TRACK 4
Accelerate Drug Discovery Through Multi OMICs, NAMs & AI Toxicity Predictions
Our efforts to reimagine preclinical safety screening with humanized ACM, multiparametric data, and AI will be discussed.
- Monday15June09:25 - 09:50TRACK 7
A Novel OncoLytic Peptide Platform - Immunogenic Cell Death Initiation For Immune Cell Recruitment
• Novel Oncolytic Peptide therapies for hard to treat cancers • Membrane-Lytic Peptides and immunogenic cell death • Reprogramming the local tumour microenvironment for systemic re…
- Monday15June09:25 - 09:50TRACK 2
Assays Around The Clock: Autonomous Robotics In Merck's Early Drug Discovery
Autonomous Mobile Robots (AMRs) transform research by automating routine tasks and extending operational hours to nights and weekends. We are implementing our first AMR, integratin…
- Monday15June09:25 - 09:50TRACK 6
From Discovery To Development: Making Partnerships Work
The presentation covers why partnerships are important and gives an overview of the key steps to a partnership addressing some do's and don'ts.
- Monday15June09:25 - 09:50TRACK 3
Generative Molecular Design – Advancing From Hits To Leads
Generative AI streamlines early-phase drug discovery by unifying molecular design and synthetic planning to navigate chemical space more efficiently than traditional methods. Integ…
- Monday15June09:25 - 09:50TRACK 1
Identification & Validation Of New E3 Ligase Ligands For Next-Generation PROTAC Development
- Use of DEL-ML and eASMS for ligand identification - Validation workflow of PROTACs
- Monday15June09:25 - 09:50TRACK 1
Lab Digitalisation & AI
- Monday15June09:25 - 09:50TRACK 8
Predictive Stability Of Glycoconjugate Vaccine Using Advanced Kinetics Modeling And High-Throughput Screening
Integrating high-throughput screening with advanced kinetics modeling enables efficient, robust predictive stability modeling for glycoconjugate vaccines and this can be applied to…
An audience of 97 companies, parsed from the program.
97 companies in attendance.
The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.